Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Poll|February 8, 2021
Poll: On the Realities of Legalizing Marijuana
Author(s)Psychiatric Times Editors
Key Takeaways
- Personalized treatment strategies are crucial in managing lung cancer brain metastases, enhancing patient outcomes.
- Targeted therapies and immunotherapies offer effective, less invasive alternatives to traditional treatments.
What are your thought about navigating these uncharted waters?
Advertisement
Do you believe legalizing marijuana is a good thing?
Advertisement
Related to this article
Don't miss out on these CME articles! Test your knowledge here.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Defining Treatment-Resistant Depression In Adults
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
4
Closing the Diagnostic Gap in Dementia With Blood-Based Biomarkers
5